Biosplice sees a pair of osteoarthritis tests fail

Biosplice’s bid to transform the treatment of everything from arthritis to cancer hit a snag this week, as the San Diego biotech announced that its experimental osteoarthritis drug failed to benefit patients in two Phase 3 clinical trials.

The results, presented at the American College of Rheumatology conference in Philadelphia, show that the small molecule drug lorecivivin failed to significantly relieve the pain of osteoarthritis patients. Both studies were randomized, placebo-controlled trials conducted at multiple medical research centers—the gold standard of scientific evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days for free!


Leave a Comment

Your email address will not be published. Required fields are marked *